ICD10 code of Sanfilippo Syndrome and ICD9 code

Sanfilippo Syndrome (Mucopolysaccharidosis Type III or MPS III) is classified under the ICD-10 code E76.210 for MPS III type A, E76.211 for type B, E76.212 for type C, and E76.213 for type D. In the older ICD-9-CM classification system, Sanfilippo Syndrome is categorized under code 277.5, which represents Mucopolysaccharidosis.

What is the clinical significance of these diagnostic codes?

While ICD codes like those for Sanfilippo Syndrome are primarily used for medical billing, insurance authorization, and public health tracking, they serve as a critical bridge for families navigating the healthcare system. Because Sanfilippo Syndrome is a rare, progressive, neurodegenerative lysosomal storage disorder, having the correct, specific ICD-10 code is essential for securing access to specialized care, multidisciplinary teams, and potential enrollment in clinical trials. Accurate coding ensures that the specific subtype (A, B, C, or D) is documented, which is vital as research into gene therapy and enzyme replacement therapy often targets specific genetic variants.

What are the primary characteristics of Sanfilippo Syndrome?

Sanfilippo Syndrome is characterized by the body’s inability to properly break down long chains of sugar molecules called heparan sulfate. This leads to the accumulation of these sugars in cells, causing widespread cellular damage. The clinical progression of Sanfilippo Syndrome often involves:

• Neurological decline: Gradual loss of cognitive skills, severe insomnia, and behavioral challenges like hyperactivity.


• Physical symptoms: Coarse facial features, enlarged head (macrocephaly), and recurring respiratory infections.


• Systemic impact: Progressive loss of motor skills, joint contractures, movement disorders, and potential seizures.


• Autonomic and sensory issues: Challenges with toileting, vision impairment, and chronic digestive disturbances.

How is Sanfilippo Syndrome diagnosed and managed?

Diagnosis typically begins with clinical suspicion followed by urine analysis for heparan sulfate, confirmed by enzymatic activity assays or genetic testing to identify mutations in the SGSH, NAGLU, HGSNAT, or GNS genes. Currently, there is no cure, and management is largely supportive. However, the 114 members of the DiseaseMaps.org community living with Sanfilippo Syndrome highlight the importance of early intervention. Investigational therapies, including gene therapy and enzyme replacement therapy, are being explored in clinical trials to address the underlying enzymatic deficiencies.

What research is currently underway for Sanfilippo Syndrome?

Research into Sanfilippo Syndrome is rapidly evolving, with a focus on mitigating the neurodegenerative effects of the disease. Current areas of investigation include:

1. Gene Therapy: Designed to provide a functional copy of the missing enzyme.


2. Enzyme Replacement Therapy: Specifically being studied for types A and B.


3. Substrate Reduction Therapy: Utilizing compounds like genistein isoflavones or Miglustat to reduce the production of heparan sulfate.


4. Autophagy Induction: Trials involving trehalose to help cells clear stored materials.

Next steps

• Consult a metabolic geneticist or a pediatric neurologist to confirm your specific subtype and discuss current clinical trial eligibility.


• Connect with the DiseaseMaps.org community to share experiences and find support from other families navigating the challenges of Sanfilippo Syndrome.


• Register with the National MPS Society or similar international foundations to stay updated on emerging research and patient advocacy efforts.


• Maintain a multidisciplinary care team, including physical and occupational therapists, to manage the progressive physical symptoms associated with Sanfilippo Syndrome.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with a qualified healthcare professional regarding any medical condition or treatment.

References

• Orphanet: Mucopolysaccharidosis type III (ORPHA:581)


• NIH Genetic and Rare Diseases Information Center (GARD): Sanfilippo syndrome


• OMIM (Online Mendelian Inheritance in Man): Mucopolysaccharidosis IIIA, IIIB, IIIC, and IIID


• National MPS Society: Resources and Research updates on Sanfilippo Syndrome